The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the
clinical outcome compared with standard of care second-line therapy in patients with
relapsed/refractory DLBCL.

The purpose of this trial is to compare the morbidity and mortality of CRS-HIPEC using
mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Morbidity and
mortality will measured using the Comprehensive Complication Index (CCI) score, Common
terminology criteria for adverse events (CTCAE version 4.03), and the Clavien-Dindo

The purpose of this study is to compare relapse-free survival between participants with
FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem
cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after
the time of engraftment for a two year period.

The primary objective of this study is to demonstrate that ultra-hypofractionation of
prostate cancer does not increase urinary toxicity as defined by the EPIC-26 GU domain
patient reported outcome.

The purpose of this study is to learn if the stoma boot camp is a good and effective way to
help people adapt to life with a stoma after surgery.

The primary objective of this study is to describe the rate of local control in patients with
her-2 positive early stage breast cancer with a complete response to chemotherapy and
lumpectomy alone.

To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

The goal of this study is to find the best ways to increase colorectal cancer (CRC)

The purpose of this study is to create a registry, which is a "bank" of information about
patients who have had similar medical conditions and treatments. The registry will be used by
researchers to learn more about long term outcome of patients with bladder cancer, how
bladder cancer tissues are related to tumor development, recurrence and survival.

The purpose of this study is to learn if lifestyle changes and counseling along with standard
medical care, compared to standard medical care alone, can prevent heart problems and
diabetes in men who are receiving ADT for prostate cancer treatment.